The ASCO20 Virtual Education Program took place Aug. 8–10. Here are some of the trending titles that have people talking.
Although colorectal cancer mortality (CRC) in the United States as a whole is on the decline, increases have been observed in diagnoses among patients aged younger than 50 years—defined as early-onset CRC. An estimated 3,640 patients will die from early-onset CRC this year alone. An Education Session titled, “Colorectal Cancer in Young Adults: A Distinct Entity” discussed early-onset CRC, including screening and diagnosis rates as well as strategies to reduce early-onset CRC. (Read more here: Education and Communication Key in Reversing Trends in Early-Onset Colorectal Cancer)
About 19% of cancer patients have a RAS mutation, point to a a significant need for treatments for these cancers. An Education Session, “ASCO/American Association for Cancer Research (AACR) Joint Session: Targeting RAS–Driven Cancers,” discussed the latest news in the treatment landscape for RAS-mutant cancers. (Read more here: New Treatment Strategies Target RAS–Driven Cancers)
In a video, Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, talks about the ADAURA study as well as other recent data regarding targeted therapies for non-small cell lung cancer (NSCLC). (Watch here: ASCO 2020 | Targeted therapy in NSCLC at ASCO 2020)
During an OncLive video program, Joshua M. Bauml, MD, assistant professor of medicine, Perelman School of Medicine, University of Pennsylvania, discussed NSCLC updates highlighted during the 2020 ASCO Virtual Scientific Program. Dr. Bauml and other experts talked about the ADAURA trial, looking ahead at NSCLC treatment, and more. (Read more here: ASCO 2020 Data Drive New Discussions in NSCLC)
Bispecific T-cell engager (BiTE®) technology can be beneficial for cancer patients who may not see success with current treatments. This video, presented by Amgen, describes the BiTE® immuno-oncology platform and how it can aid these patients. (Watch here: BiTE® Immuno-Oncology Platform: Designed to Engage the Natural Power of T-Cells)
Continue the conversation on social media using the hashtag #ASCO20